| Gene Symbol | SIGLEC |
| Full Name | 3 Modulation Therapy for Neurodegeneration |
| GeneCards | SIGLEC |
| Human Protein Atlas | SIGLEC |
| Phagocytosis | SIGLEC-3 activation reduces clearance of amyloid-beta plaques and cellular debris[@griciuc2013] |
| Cytokine production | Suppresses pro-inflammatory cytokine release including TNF-α, IL-1β, and IL-6[@zhou2022] |
| Cellular proliferation | Inhibits microglial proliferation and survival signals[@wu2023] |
| CD33 knockout mice | CD33-deficient mice show enhanced microglial clearance of amyloid-beta and reduced plaque burden[@liu2022] |
| Human genetics | The protective rs3865444*C allele reduces SIGLEC-3 expression and is associated with decreased AD risk[@malik2023] |
| Expression studies | Higher microglial CD33 expression correlates with more severe amyloid pathology in AD brains[@chan2015] |
| Anti-CD33 antibodies | Monoclonal antibodies blocking CD33-sialic acid interactions enhance microglial phagocytosis in vitro[@huang2021] |
| Therapeutic antibodies | Anti-CD33 antibodies (similar to those used in AML) have been proposed for AD treatment[@biran2022] |
| Brain penetration | Key challenge - anti-CD33 antibodies show limited blood-brain barrier (BBB) penetration in mouse models[@pardridge2024] |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |